Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717125 | 1.00 | KDM4E (0.55) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL18288087 | 0.94 | NPC1 (0.51) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL7558044 | 0.90 | HPGD (0.58) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL30898565 | 0.85 | MAPT (0.53) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL34895 | 0.85 | MAPT (0.53) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL28040989 | 0.83 | HPGD (0.48) | KDM4ENPC1MEN1KMT2APOLB | |
| SCHEMBL30504311 | 0.83 | LCK (0.56) | KDM4ENPC1ALDH1A1HPGDMAPT | |
| Methyl Alcohol SCHEMBL7181550 | 0.81 | KDM4E (0.69) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL18758 | 0.81 | KDM4E (0.68) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6916181 | 0.81 | KDM4E (0.68) | KDM4EMEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116367832-A | Substituted heteroaryl compounds and uses thereof | 苏州华明道康生物医药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022078294-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-3081987-B1 | CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION USING NOVEL ONIUM SALT AND RESIST PATTERN FORMING PROCESS | SHINETSU CHEMICAL CO (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-9740098-B2 | Chemically amplified negative resist composition using novel onium salt and resist pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9740098-B2 | Chemically amplified negative resist composition using novel onium salt and resist pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9720323-B2 | Chemically amplified positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9720323-B2 | Chemically amplified positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9665002-B2 | Onium salt compound, resist composition, and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| WO-2012061390-A2 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
| US-20100048604-A1 | Ligands for Aldoketoreductases | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2010-02-25 | — | — | US | disclosed |
| US-20100048604-A1 | Ligands for Aldoketoreductases | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2010-02-25 | — | — | US | disclosed |
| US-20070270332-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | VALLEE BERT L | 2007-11-22 | — | — | US | disclosed |
| EP-1077697-B1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1645272-A2 | Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1077697-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6121010-A | SCREENING FOR COMPOUNDS WHICH REDUCE ALCOHOL (ETHANOL) CONSUMPTION BY DETERMINING EFFECTIVENESS FOR INHIBITING ALDEHYDE DEHYDROGENASE ACTIVITY ON ALDEHYDES DERIVED FROM SUBSTRATES OF MONOAMINE OXIDASE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999058124-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048604-A1 | Ligands for Aldoketoreductases | AKR1C2, AKR1C1, AKR1B1 | KDM4E 2592/4885NPC1 539/4885MEN1 2261/4885 |
| US-20070270332-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | ADH1A, ADH5, ADH1C | KDM4E 4474/4885NPC1 2189/4885MEN1 4162/4885 |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | KDM4E 2480/4885NPC1 853/4885MEN1 2371/4885 |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | KDM4E 137/4885NPC1 4606/4885MEN1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.